This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
by Kinjel Shah
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.
pharmaceuticals
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
by Zacks Equity Research
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
pharmaceuticals
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
by Zacks Equity Research
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
biotechnology biotechs medical pharmaceuticals
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
by Kinjel Shah
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
pharmaceuticals
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
by Zacks Equity Research
Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms
biotechnology medical pharmaceuticals
Pharma ETF (FTXH) Hits New 52-Week High
by Sanghamitra Saha
Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
etfs pharmaceuticals
Bull of the Day: Collegium Pharmaceutical (COLL)
by Shaun Pruitt
This medical stock has been seeing strong momentum but is still cheaply valued and may serve as a further hedge against recent market jitters.
earnings investing medical pharmaceuticals
Top Research Reports for Microsoft, Amazon.com & Eli Lilly
by Mark Vickery
Microsoft shines in Zacks' top picks as strong cloud and AI momentum drive standout quarterly results and reinforce long-term growth potential.
computers pharmaceuticals retail
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
by Zacks Equity Research
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
medical pharmaceuticals
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
by Zacks Equity Research
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
biotechnology biotechs medical pharmaceuticals